Ticker

An independent study has found that tumour cells circulating in the blood of patients with the most aggressive form of brain cancer can be captured and analysed using technology made by CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company. Glioblastoma rarely spreads beyond the brain, which had made blood-based detection of the disease an unlikely prospect.

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company, said an independent study had shown its Parsortix system can detect the biological targets used by a fast-growing class of cancer drugs on tumour cells captured from patients' blood. The peer-reviewed research, published in The Journal of Liquid Biopsy, was carried out by researchers at Trinity College Dublin and St James's Hospital, Dublin.

The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish. The heavy lifting is done.

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the cancer diagnostics company, has told shareholders it remains on track to deliver revenues of at least £2.1 million for 2026 as it searches for a new chief executive. The figure would represent a 50% increase on 2025.